8-K: Krystal Biotech Secures Japanese Approval for VYJUVEK Gene Therapy in Dystrophic Epidermolysis Bullosa

Krystal Biotech announced that Japans Ministry of Health, Labour and Welfare has granted marketing authorization for VYJUVEK, its gene therapy for Dystrophic Epidermolysis Bullosa, marking a significant expansion into the Asian market.

Summary

• Krystal Biotech received marketing authorization from Japan's Ministry of Health, Labour and Welfare (MHLW) for VYJUVEK (beremagene geperpavec-svdt) for the treatment of Dystrophic Epidermolysis Bullosa (DEB) patients, starting from birth.
• VYJUVEK is the first genetic medicine approved in Japan for the treatment of DEB.
• The therapy is designed to address the root cause of DEB by delivering functional copies of the human COL7A1 gene to promote wound healing and sustained functional type VII collagen protein expression with redosing.
• The Japanese approval allows for flexible administration options, including dosing at home or in a healthcare setting, with the option for administration by patients or their family members.
• Approval for home administration was granted after regulatory evaluation and environmental safety confirmation for type 1 use regulation in accordance with the Cartagena Act.
• Genetic testing is not a requirement for treatment with VYJUVEK.
• Commercial launch in Japan is expected by the end of 2025, contingent upon the completion of reimbursement procedures.
• The MHLW approval was based on a comprehensive clinical dataset, including results from an open-label extension study conducted in Japanese patients, which mirrored prior clinical experience from the US Phase 3 study.
• All four patients who completed the Japanese open-label study achieved the primary study endpoint of full wound closure at six months.
• VYJUVEK was well tolerated and exhibited a safety profile in Japanese patients consistent with previous studies.
• A ten-year re-examination period applies to VYJUVEK in Japan.
• VYJUVEK was previously approved by the Food and Drug Administration in the United States in May 2023 and by the European Commission in April 2025.

Sentiment

Score: 9

Explanation: The approval of VYJUVEK in Japan is a highly significant positive development for Krystal Biotech, opening a new major market for its flagship gene therapy. It reinforces the therapy's global validation and commercial potential, with strong clinical data supporting the approval and flexible administration options. The only minor caveat is the pending reimbursement procedures, which is standard for drug launches.

Positives

• VYJUVEK is the first and only genetic medicine approved in Japan for the treatment of Dystrophic Epidermolysis Bullosa (DEB), addressing a significant unmet medical need.
• The approval expands VYJUVEK's global market presence, following successful approvals in the United States and Europe.
• Flexible administration options, including home dosing by patients or family members, enhance patient access and convenience.
• Clinical data from the Japanese open-label extension study demonstrated strong efficacy, with all four patients completing the study achieving full wound closure at six months, consistent with US Phase 3 results.
• The therapy exhibited a favorable and consistent safety profile in Japanese patients.
• A ten-year re-examination period in Japan provides long-term market stability and exclusivity.

Risks

• The timing for availability of VYJUVEK in Japan depends on the completion of reimbursement procedures currently underway.
• Actual results may differ materially from forward-looking statements due to various important factors, including uncertainties related to reimbursement for VYJUVEK.

Future Outlook

Krystal Biotech expects to commercially launch VYJUVEK in Japan by the end of 2025, pending completion of reimbursement procedures. The company is making tremendous progress towards its goal of improving outcomes for DEB patients around the world, with recent approvals now in both Japan and Europe.

Management Comments

• "For far too long, DEB patients in Japan have suffered from a lack of corrective therapies to manage their complex and often debilitating disease. The approval of VYJUVEK in Japan is a long-awaited and urgently needed breakthrough, offering the potential to dramatically improve the lives of DEB patients across the country. With this important milestone, we remain on track to commercially launch VYJUVEK in Japan later this year and bring this innovative therapy to the many hundreds of DEB patients in need." Hiroshi Kasamoto, General Manager of Japan at Krystal Biotech.
• "The approval of VYJUVEK in Japan is another important milestone for our organization and the DEB patients we serve. With recent approvals now in both Japan and Europe, we are making tremendous progress towards our goal of improving outcomes for DEB patients around the world." Suma Krishnan, President of Research and Development at Krystal Biotech.

Industry Context

This approval signifies a major advancement in the rare disease and gene therapy landscape, particularly for Dystrophic Epidermolysis Bullosa (DEB), a severe genetic skin disorder with high unmet medical needs. It positions Krystal Biotech as a global leader in gene therapy for DEB, expanding its market reach beyond the US and Europe into the significant Asian market. This also highlights the increasing global regulatory acceptance and commercialization potential for advanced genetic medicines.

Comparison to Industry Standards

• VYJUVEK is the first and only genetic medicine approved in Japan for the treatment of DEB, setting a new standard for therapeutic options in this market.
• The approval for home administration after environmental safety confirmation under the Cartagena Act is a notable achievement, demonstrating a flexible and patient-centric approach to gene therapy delivery, which is not universally common for such advanced therapies.
• Clinical results from the Japanese open-label extension study, showing 100% wound closure at six months for patients completing the study, are consistent with prior clinical experience, including the US Phase 3 study, indicating robust and reproducible efficacy across different patient populations.
• The safety profile in Japanese patients was consistent with previous studies, reinforcing the therapy's favorable tolerability across diverse demographics.

Stakeholder Impact

• Shareholders: Positive impact due to expanded market access, increased revenue potential, and validation of the company's lead product.
• Patients (DEB patients in Japan): Highly positive impact as VYJUVEK is the first genetic medicine approved in Japan for DEB, offering a corrective therapy for a debilitating disease, with flexible administration options including home dosing.
• Employees: Positive impact due to company growth, expanded operations, and successful product commercialization.

Next Steps

• Completion of reimbursement procedures in Japan.
• Commercial launch of VYJUVEK in Japan by the end of 2025.
• Continued progress towards improving outcomes for DEB patients globally.

Key Dates

Recommendation

The approval of VYJUVEK in Japan represents a significant commercial and clinical milestone for Krystal Biotech. As the first genetic medicine for Dystrophic Epidermolysis Bullosa in Japan, it addresses a critical unmet medical need in a major market, following successful launches in the US and Europe. This global expansion, coupled with robust clinical data and flexible administration options, substantially increases the company's revenue potential and strengthens its market position in the rare disease gene therapy space. The positive regulatory momentum and clear path to commercialization in Japan make this a highly attractive investment opportunity.

Keywords

Krystal Biotech, VYJUVEK, Dystrophic Epidermolysis Bullosa, DEB, gene therapy, genetic medicine, Japan, MHLW, rare disease, biotechnology, COL7A1, orphan drug